• 1
    Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807814.
  • 2
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.
  • 3
    Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72(12 Suppl): S8993.
  • 4
    London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403406.
  • 5
    Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623628.
  • 6
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 27152729.
  • 7
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557565.
  • 8
    Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580590.
  • 9
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 10
    Devlin J, Doherty D, Thomson L et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926933.
  • 11
    Takatsuki M, Uemoto S, Inomata Y et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449454.
  • 12
    Owens ML, Maxwell JG, Goodnight J, Wolcott MW. Discontinuance of immunosuppression in renal transplant patients. Arch Surg 1975; 110: 14501451.
  • 13
    Uehling DT, Hussey JL, Weinstein AB, Wank R, Bach FH. Cessation of immunosuppression after renal transplantation. Surgery 1976; 79: 278282.
  • 14
    Zoller KM, Cho SI, Cohen JJ, Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: A national survey. Kidney Int 1980; 18: 110114.
  • 15
    Starzl TE, Murase N, Demetris AJ et al. Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 2004; 77: 926929.
  • 16
    Burlingham WJ, Grailer AP, Fechner JH, Jr. et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995; 59: 11471155.
  • 17
    Christensen LL, Grunnet N, Rudiger N, Moller B, Birkeland SA. Indications of immunological tolerance in kidney transplantation. Tissue Antigens 1998; 51: 637644.
  • 18
    Fischer T, Schobel H, Barenbrock M. Specific immune tolerance during pregnancy after renal transplantation. Eur J Obstet Gynecol Reprod Biol 1996; 70: 217219.
  • 19
    Strober S, Benike C, Krishnaswamy S, Engleman EG, Grumet FC. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity. Transplantation 2000; 69: 15491554.
  • 20
    VanBuskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145155.
  • 21
    Brouard S, Dupont A, Giral M et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5: 330340.
  • 22
    Calne RY. Prope tolerance: The future of organ transplantation—from the laboratory to the clinic. Transplantation 2004; 77: 930932.
  • 23
    Cortesini R, Suciu-Foca N. The concept of "partial" clinical tolerance. Transpl Immunol 2004; 13: 101104.
  • 24
    Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 15021510.
  • 25
    Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: Comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004; 77: 786789.
  • 26
    Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: A multicenter study. Transplantation 1998; 66: 17181726.
  • 27
    Siegal BR, Greenstein SM. Postrenal transplant compliance from the perspective of African-Americans, Hispanic-Americans, and Anglo-Americans. Adv Ren Replace Ther 1997; 4: 4654.
  • 28
    Chisholm MA, Vollenweider LJ, Mulloy LL et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000; 70: 12401244.
  • 29
    Vlaminck H, Maes B, Evers G et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4: 15091513.
  • 30
    Carter JT, Lee CM, Weinstein RJ, Lu AD, Dafoe DC, Alfrey EJ. Evaluation of the older cadaveric kidney donor: The impact of donor hypertension and creatinine clearance on graft performance and survival. Transplantation 2000; 70: 765771.
  • 31
    Rao KV, Kasiske BL, Odlund MD, Ney AL, Andersen RC. Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 1990; 49: 9195.
  • 32
    Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW. Significance of the donor age effect on kidney transplants. Clin Transplant 1997; 11(5 Pt 1): 366372.
  • 33
    Roels L, Waer M, Coosemans W, Christiaens MR, Vanrenterghem Y. The influence of donor age on initial and long-term renal allograft outcome. Leuven Collaborative Group for Transplantation. Transpl Int 1994; 7(Suppl 1): S303305.
  • 34
    Koning OH, Ploeg RJ, Van Bockel JH et al. Risk factors for delayed graft function in cadaveric kidney transplantation: A prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997; 63: 16201628.
  • 35
    Roussey-Kesler G, Ballet C, Aubin JT et al. Humoral and cellular response to influenza vaccination in human recipients naturally tolerant to a kidney allograft (Abstract). Basic Science Symposium, La Baule, France 2005.
  • 36
    Opelz G, Terasaki PI. Dominant effect of transfusions on kidney graft survival. Transplantation 1980; 29: 153158.
  • 37
    Soulillou JP, Bignon JD, Peyrat MA, Guimbretiere J, Guenel J. Systematic transfusion in hemodialyzed patients awaiting grafts: Kinetics of anti-t and b lymphocyte immunization and its incidence on graft function. Transplantation 1980; 30: 285289.
  • 38
    Fehrman I, Ringden O, Moller E. Blood transfusions as pretreatment for kidney transplantation: Immunization rate and effect on cellular immune response in vitro. Transplantation 1983; 35: 339343.
  • 39
    Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438443.
  • 40
    Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of the development of donor-specific and non donor-specific HLA antibodies after kidney transplantation. J. Am. Soc. Nephrol 2005; in press.
  • 41
    Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol 2004; 13: 117130.
  • 42
    Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 2003; 14: 16431651.
  • 43
    Baeten D, Louis S, Braud C et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long term drug-free tolerance and chronic rejection in human kidney graft recipients. J. Am. Soc. Nephrol. 2005, in press.
  • 44
    Schwarz A. Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 8: 1992.
  • 45
    Li Y, Koshiba T, Yoshizawa A et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 21182125.
  • 46
    Derks RA, Burlingham WJ. In vitro parameters of donor-antigen-specific tolerance. Curr Opin Immunol. 2005; 17: 560.
  • 47
    McLaughlin K, Wu C, Fick G, Muirhead N, Hollomby D, Jevnikar A. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation. 2002; 74: 813816.